Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2Breast 2Thoracic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Advanced Breast Cancer 1

Interventions

Letrozole 34Fulvestrant 31Specimen Handling 29ribociclib 22pembrolizumab 22Paclitaxel 21Magnetic Resonance Spectroscopy 20palbociclib 19Trastuzumab 19Anastrozole 19Carboplatin 18Capecitabine 18exemestane 17abemaciclib 16Biopsy 16Tamoxifen 15pertuzumab 14trastuzumab deruxtecan 12Cyclophosphamide 10Taxes 9Radiotherapy 8Goserelin 8Docetaxel 8giredestrant 7Standard of Care 7130-nm albumin-bound paclitaxel 7inavolisib 6eribulin 6elacestrant 6atezolizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
AZD5305 × Breast × 30 days × Clear all
NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡